Jason Gerberry
Stock Analyst at B of A Securities
(3.96)
# 590
Out of 5,090 analysts
165
Total ratings
58.82%
Success rate
8.05%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $42 → $62 | $61.44 | +0.91% | 3 | Dec 1, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $230 → $247 | $169.70 | +45.55% | 6 | Nov 18, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $21.68 | +33.76% | 4 | Nov 13, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $81 → $83 | $81.68 | +1.62% | 6 | Sep 23, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $28 → $32 | $26.77 | +19.54% | 2 | Aug 26, 2025 | |
| IMVT Immunovant | Maintains: Buy | $33 → $30 | $22.84 | +31.35% | 6 | Aug 12, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $49 | $9.55 | +413.09% | 2 | Aug 12, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $173 → $176 | $149.22 | +17.95% | 6 | Aug 5, 2025 | |
| PROK ProKidney | Downgrades: Underperform | $3 → $1 | $2.34 | -57.26% | 4 | Jun 30, 2025 | |
| LQDA Liquidia | Maintains: Buy | $25 → $23 | $34.41 | -33.16% | 2 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $46 | $44.36 | +3.70% | 3 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $22 | $28.46 | -22.70% | 14 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $46.48 | +194.75% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $10.93 | -8.51% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $23.53 | +27.50% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $100 | $69.56 | +43.76% | 5 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $7.68 | +212.50% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $31.59 | -1.87% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $4.27 | +12,780.56% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $29.52 | -1.76% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $45.01 | +24.42% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $39.83 | -24.68% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $100 → $50 | $8.42 | +493.82% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $1,010.31 | -50.51% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.43 | +529.37% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $7.14 | +250.14% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.99 | +151.26% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $6.93 | +289.61% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.20 | +1,566.67% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $8.81 | +1,035.07% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $226.08 | -57.98% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $52.15 | +15.05% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $26.03 | +42.14% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $99.72 | -9.75% | 11 | Oct 17, 2019 |
Arrowhead Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $42 → $62
Current: $61.44
Upside: +0.91%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $230 → $247
Current: $169.70
Upside: +45.55%
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $21.68
Upside: +33.76%
Ionis Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $81 → $83
Current: $81.68
Upside: +1.62%
Amphastar Pharmaceuticals
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $26.77
Upside: +19.54%
Immunovant
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $22.84
Upside: +31.35%
Biohaven
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $9.55
Upside: +413.09%
Axsome Therapeutics
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $149.22
Upside: +17.95%
ProKidney
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $2.34
Upside: -57.26%
Liquidia
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $34.41
Upside: -33.16%
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $44.36
Upside: +3.70%
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $28.46
Upside: -22.70%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $46.48
Upside: +194.75%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $10.93
Upside: -8.51%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $23.53
Upside: +27.50%
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $69.56
Upside: +43.76%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $7.68
Upside: +212.50%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $31.59
Upside: -1.87%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $4.27
Upside: +12,780.56%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $29.52
Upside: -1.76%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $45.01
Upside: +24.42%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $39.83
Upside: -24.68%
Aug 8, 2023
Downgrades: Underperform
Price Target: $100 → $50
Current: $8.42
Upside: +493.82%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $1,010.31
Upside: -50.51%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.43
Upside: +529.37%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $7.14
Upside: +250.14%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.99
Upside: +151.26%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $6.93
Upside: +289.61%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.20
Upside: +1,566.67%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $8.81
Upside: +1,035.07%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $226.08
Upside: -57.98%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $52.15
Upside: +15.05%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $26.03
Upside: +42.14%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $99.72
Upside: -9.75%